skip to main content
Banner Image

Faculty investigators

Srihari S Naidu, MD



Cardiovascular & Health Outcomes


Faculty Investigators

Primary Address

120 Mineola Blvd, Suite 500
Mineola, NY 11501
Get Directions
View Map



Bio - Srihari Naidu, MD

Srihari S. Naidu, MD, Director of the Cardiac Catheterization Laboratory, Interventional Cardiology Fellowship Program, and Hypertrophic Cardiomyopathy Center at Winthrop-University Hospital is skilled in all aspects of interventional cardiology including atrial septal defect (ASD) and patent foramen ovale (PFO) closure, alcohol septal ablation for hypertrophic cardiomyopathy, aortic and mitral valvuloplasty, percutaneous ventricular assist devices, as well as peripheral and coronary intervention.

Prior to joining Winthrop in 2006, he was Assistant Professor of Medicine in the Division of Cardiology at New York Presbyterian Hospital-Weill Cornell Medical Center, where he was the second highest volume operator and developed their Hypertrophic Cardiomyopathy Center, performing Cornell’s first series of alcohol septal ablations. Dr. Naidu is Board Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology, and is currently Assistant Professor of Medicine at SUNY – Stony Brook School of Medicine.

His post-graduate training included fellowships in interventional cardiology and general cardiology at the University of Pennsylvania Medical Center, where he received the 2004 Outstanding Teaching Award. He completed his residency in internal medicine at New York Hospital-Cornell Medical Center, and received his undergraduate and medical degrees from Brown University, where he remains associated as a Member of the Medical School Board of Directors and President of the Undergraduate Class of 1993.

A Fellow of the American College of Cardiology (FACC), American Heart Association (FAHA), Society for Cardiovascular Angiography and Intervention (FSCAI), and American College of Chest Physicians (FCCP), Dr. Naidu serves on several nationally-appointed committees, including the ACC Interventional Science Council, AHA Scientific Program Committee, and TCT State Representative and Advisory Board.

Description of Research Interests/Activities

As a recognized expert in the management of patients with Hypertrophic Cardiomyopathy, Dr. Naidu runs a comprehensive, multi-disciplinary Hypertrophic Cardiomyopathy Center, deemed a Center of Excellence by the Hypertrophic Cardiomyopathy Association (HCMA). The Center treats well over 125 patients and families with this rare genetic disease from the tri-state area and beyond. For his expertise in the performance of alcohol septal ablation, a minimally-invasive alternative to open-heart surgery, Dr. Naidu was selected to represent the Society for Cardiovascular Angiography and Intervention (SCAI) on the 2010 American Heart Association / American College of Cardiology Guideline Writing Committee for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy.

Dr. Naidu has published over 70 original articles, book chapters and abstracts dealing with angioplasty outcomes, new technology and innovative procedural modifications. His research interests include outcomes in hypertrophic cardiomyopathy, as well as outcomes in patients treated for persistent atrial septal defect or patent foramen ovale. At Winthrop, Dr. Naidu created a registry of patients treated with percutaneous PFO closure for cryptogenic stroke, in order to more fully understand this disease state. In addition, Dr. Naidu performs research utilizing the NYS and NHLBI Angioplasty Registries, comparing contemporary outcomes between various angioplasty devices, including drug-eluting stents.

Dr. Naidu has also brought multiple randomized controlled clinical trials to Winthrop, including the FREEDOM trial comparing angioplasty to surgery for diabetic patient with multi-vessel disease, the Impella PROTECT 2 trial, comparing angioplasty with our without percutaneous ventricular assist device placement, the PFO Access Registry for patients with recurrent stroke, and the HCRI DAPT study evaluating optimal duration of anti-platelet therapy after stent placement.

Dr. Naidu is a recognized national expert on interventional cardiology topics including angioplasty, stent placement, drug-eluting stents, anti-platelet therapy, and structural heart intervention, and regularly lectures throughout the United States and Europe. In addition, he has written numerous guest editorials and invited reviews on these topics. Due to this expertise, he routinely serves as Invited Faculty for the American College of Cardiology (ACC), American Heart Association (AHA), Transcatheter Cardiovascular Therapeutics (TCT), and Society for Cardiovascular Angiography and Intervention (SCAI) Scientific Sessions.

Areas of Experience

Health Outcomes
Structural Heart Disease
Clinical Practice Guidelines

Clinical Practice and Interests

Dr. Naidu sees patients two days a week, with one day dedicated to patients with Hypertrophic Cardiomyopathy. In addition to patients with this disease, his practice also focuses on patients who might require other advanced interventional procedures, including angioplasty, stenting, valvuloplasty, biopsy, alcohol septal ablation, or ASD/PFO closure. Dr. Naidu also sees general cardiology patients as time and availability permit.

Dr. Naidu also runs the Interventional Cardiology Fellowship Program, training two interventional fellows per year within the general cardiology program. He also is Co-Director of the Long Island Cardiology Fellows Forum, a quarterly education meeting among all academic hospitals on Long Island.


Selected Publications

26. Khouzam R, Deverapalli S, Choi D, Naidu SS. Comprehensive Hemodynamic Assessment in a Patient with Double Mechanical Valve Replacement. Circulation 2010 (submitted).

25. Khouzam R, Naidu SS. Alcohol Septal Ablation for Symptomatic Hypertrophic Obstructive Cardiomyopathy in Patients with Prior Coronary Revascularization. J Invasive Cardiol 2010 (submitted).

24. Parikh PB, Gruberg L, Jeremias A, Naidu SS, Shlofmitz RA, Brener SJ, Pappas T, Marzo KP, Brown DL. Outcomes in Male versus Female Dialysis-dependent Patients Undergoing Percutaneous Coronary Intervention. Am J Cardiol 2010 (submitted).

23. Baldwin D, Abbott J, Trost JC, Vlachos HA, Selzer F, Glaser R, Wilensky RL, Slater JN, Doucet S, Naidu SS, Aronow HD, Williams DO. A Comparison of Drug-eluting and Bare Metal Stents for Saphenous Vein Graft Lesions: A Report from the National Heart, Lung, and Blood Institute Dynamic Registry. Am J Cardiol 2010 (submitted).

22. Naidu SS, Turco MA, Mauri L, Coolong A, Popma JJ, Kereiakes DJ. Contemporary Incidence and Predictors of Major Adverse Cardiac Events Following Saphenous Vein Graft Intervention with Embolic Protection (An AMEthyst Trial Substudy). Am J Cardiol 2010 (in press).

21. Naidu SS. Three Years since the FDA Advisory Panel on Drug-Eluting Stents: What Have we Learned About Off-Label Use and Stent Thrombosis? J Invasive Cardiol 2010;22(1): 21-21.

20. Khouzam R, Naidu SS, Deverapalli S. Hypertrophic Cardiomyopathy: A Myocardial Bridge. Online J Card 2010

19. Naidu SS, Choi D, Angelopoulos P. Abrupt Vessel Closure: A Detailed Look at the Intraprocedural Decision-Making Required to Handle This Challenging Presentation. Cardiac Interventions Today 2009;4:17-22.

18. Naidu SS. Bare Metal vs. Drug-Coated Intracoronary Stents in Clinical Practice: Are There Guidelines? Vasc Dis Manag 2009;6(5):136-144.

17. Choi D, Dardano J, Naidu SS. Alcohol Septal Ablation Through an Anomalous Right Coronary Septal Perforator: First report and Discussion. J Invasive Cardiol 2009;21:E106-109.

16. Glaser R, Naidu SS, Selzer F, Jacobs AK, Laskey WK, Srinivas VS, Slater JN, Wilensky RL. Poorer Prognosis for Patients undergoing Primary Percutaneous Coronary Intervention during Off-Hours: The Role of Operator Fatigue. J Am Coll Cardiol Intv 2008;1:681-88.

15. Kodali V, Cohen T, Naidu SS. Alcohol Septal Ablation in the Cath Lab: What is it all About? EP Lab Digest 2008;8(5):26-30.

14. Naidu SS. The Declining Relevance of Age in the Treatment of Atrial Septal Defects. J Invasive Cardiol 2008;20(4):177-8.

13. Naidu SS, Wong SC, Steingart RM. Interventional Therapies for Heart Failure in the Elderly. Heart Fail Clin 2007;3(4):485-500.

12. Naidu SS, Wong SC, Steingart RM. Interventional Therapies for Heart Failure in the Elderly. Clin Geriatr Med 2007;23:155-178.

11. Gade CL, Bergman G, Naidu SS, Weinsaft JW, Callister TQ, Min JK. Comprehensive Evaluation of Atrial Septal Defects in Individuals Undergoing Percutaneous Repair by 64-Detector Row Computed Tomography. Int J Cardiovasc Imaging 2007;23(3):397-404.

10. Naidu SS, Polin GM, Selzer F, Laskey WK, Jacobs AK, Williams DO, Wilensky RL. Outcome of Percutaneous Coronary Intervention in Unstable Angina Pectoris Versus Stable Angina Pectoris in Two Time Periods. Am J Cardiol 2006;98(4):447-452.

9. Polin N, Feldman DN, Naidu SS. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Novel Application of the Cutting Balloon. J Invasive Cardiol 2006;18(9):56-7.

8. Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu SS, Wong SC, Hong MK. Combination Therapy with Aspirin, Clopidogrel and Warfarin Following Coronary Stenting is Associated with a Significant Risk of Bleeding. J Invasive Cardiol 2006;18(4):162-4.

7. Naidu SS, Wong SC. Novel Intracoronary Support Catheter For Complex Coronary Interventions. J Invasive Cardiol 2006;18(2):80-81.

6. Juliano N, Wong SC, Naidu SS. Alcohol Septal Ablation for Failed Surgical Myectomy. J Invasive Cardiol 2005;17(10):569-571.

5. Ilkhanoff L, Naidu SS, Rohatgi S, Silvestry F, Ross MJ, Herrmann HC. Transcatheter Device Closure of Interatrial Septal Defects for Symptomatic Hypoxemia. J Interven Cardiol 2005;18:227-232.

4. Naidu SS, Vlachos H, Faxon D, Jacobs AK, Johnston JM, Detre K, Wilensky RL. Usefulness of Non-Coronary Vascular Disease in Predicting Adverse Events in the Year Following Percutaneous Coronary Intervention. Am J Cardiol 2005;95(5):575-580.

3. Naidu SS, Rohatgi S, Herrmann HC, Glaser R. Unprotected Left Main “Kissing” Stent Implantation With a Percutaneous Ventricular Assist Device. J Invasive Cardiol 2004;16(11):683-684.

2. Naidu SS, Selzer F, Jacobs AK, Faxon D, Marks DS, Johnston JM, Detre K, Wilensky RL. Renal Insufficiency Is an Independent Predictor of Mortality After Percutaneous Coronary Intervention. Am J Cardiol 2003;92(10):1160-1164.

1. Gertz D, Fallon JT, Gallo R, Taubman MB, Banai S, Barry WL, Gimple LW, Nemerson Y, Thiruvikraman S, Naidu SS, Chesebro JH, Fuster V, Sarembock IJ, Badimon JJ. Hirudin Reduces Tissue Factor Expression in the Neointima after Balloon Injury in Rabbit Femoral and Porcine Coronary Arteries. Circulation 1998;98:580-587.